Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08KGY
|
|||
| Former ID |
DNCL002724
|
|||
| Drug Name |
PRX-302
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 3 | [1] | |
| Company |
Sophiris
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostate specific antigen (KLK3) | Target Info | Modulator | [2] |
| KEGG Pathway | Pathways in cancer | |||
| Prostate cancer | ||||
| Pathway Interaction Database | Coregulation of Androgen receptor activity | |||
| Regulation of Androgen receptor activity | ||||
| FOXA1 transcription factor network | ||||
| Reactome | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | |||
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | ||||
| WikiPathways | Prostate Cancer | |||
| Androgen receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01966614) Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH. U.S. National Institutes of Health. | |||
| REF 2 | Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2011 May;59(5):747-54. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.